Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 14/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 14/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.38 |
| ▸ | MTOR | P42345 | 4/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23541274 | 0.94 | DDB1 (0.49) | DDB1CRBNPIK3CAMTORATM | |
| SCHEMBL23540499 | 0.88 | DDB1 (0.52) | DDB1CRBNPIK3CAMTORATM | |
| SCHEMBL31701713 | 0.86 | DDB1 (0.46) | DDB1CRBNPIK3CAMTOR | |
| SCHEMBL23540862 | 0.85 | DDB1 (0.54) | DDB1CRBNPIK3CAMTORATM | |
| SCHEMBL31701469 | 0.85 | DDB1 (0.46) | DDB1CRBNPIK3CAMTOR | |
| SCHEMBL23553708 | 0.85 | DDB1 (0.56) | DDB1CRBNPIK3CAMTORATM | |
| SCHEMBL23540810 | 0.84 | CRBN (0.56) | DDB1CRBN | |
| SCHEMBL31397472 | 0.83 | DDB1 (0.49) | DDB1CRBNGSK3BDYRK1AWNT1 | |
| SCHEMBL23540624 | 0.82 | DDB1 (0.49) | DDB1CRBNMTORATMATR | |
| SCHEMBL31702313 | 0.82 | DDB1 (0.51) | DDB1CRBNPIK3CAMTORATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | ABBVIE INC. | 2024-11-21 | — | — | US | disclosed |
| CN-116194453-A | Protein tyrosine phosphatase degrading agent and method of use thereof | 卡里科生命科学有限责任公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4077319-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | Calico Life Sciences LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127586-A1 | PROTEIN TYROSINE PHOSPHATASE DEGRADERS AND METHODS OF USE THEREOF | CALICO LIFE SCIENCES LLC (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383886-A1 | Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof | PTPN5, PTPN1, PTPN2 | DDB1 1684/4885CRBN 182/4885PIK3CA 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.